Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

This study evaluated the efficacy and safety ...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Research article Source Type: research